Cipla Recalls Fosfomycin Granules Over Impurity Standards
Pharmacists must audit stock and remove the medication to comply with the FDA's latest Class II recall classification.
Updated on Oct. 15, 2026 in Consumer Goods
Live Poll
Do you trust that pharmaceutical companies are transparent when they initiate voluntary drug recalls?
Cipla has issued a voluntary recall for its Fosfomycin Tromethamine Granules for Oral Solution across the United States. The drug, used to treat acute uncomplicated urinary tract infections in women, failed to meet required impurity and degradation standards.
Why it matters
For pharmacies and healthcare providers, the Class II recall highlights the necessity of monitoring manufacturer supply chain stability. These recalls necessitate immediate inventory assessment to prevent the distribution of products that do not meet regulatory quality specifications.
The FDA categorized this as a Class II recall, indicating that while the product failed purity standards, serious health risks remain remote. The specific volume of impacted stock across the U.S. market remains unknown.
The players
Cipla
A global pharmaceutical company headquartered in New Delhi that manufactures and markets a wide range of generic drugs and active pharmaceutical ingredients.
US FDA
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and medical products through regulatory oversight.
The details
The product failed to meet established impurity and degradation standards, triggering the recall process. A Class II designation means that while the product may cause temporary or reversible adverse health consequences, the probability of serious injury is remote. Operators should audit inventory records to identify affected lots and coordinate with Cipla for removal protocols.
Timeline
October 15, 2026: Official report issued regarding the voluntary drug recall.
Market Landscape
This action follows the standard enforcement protocols set by the FDA's Class II recall framework. It underscores a broader industry trend where increased scrutiny of degradation standards forces companies to proactively remove non-compliant batches.
Pharmacy managers and healthcare operators must immediately cross-reference their current stock against the specific lot numbers identified in the recall documentation. Ensure these products are sequestered from active inventory to maintain compliance with FDA standards.
The takeaway
Reliable inventory tracking is a critical defense against supply chain disruptions when manufacturers issue quality-driven recalls. Operators should verify that internal recall notification systems are synced with the FDA Enforcement Report to receive updates on affected product batches in real time.
Further reading
For broader trends in quality management, review the Consumer Goods section.
Source note: This article includes information reported by ETPharma.
Live Poll
Do you trust that pharmaceutical companies are transparent when they initiate voluntary drug recalls?
